

Abstract

The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of
5 medicaments for the treatment of angiodependent diseases. More specifically, the invention
relates to the use of the aforesaid compound and, in particular, the calcium and potassium
salts thereof, for the treatment of two angiodependent diseases, which present a reduction in
the apoptosis, namely cancer and psoriasis. The invention also discloses the
antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of
10 compounds in non-quiescent cells. In addition, the invention details the potentiating effect
of said compounds on known cytostatic medicines in the treatment of tumours and,
specifically, on gliomas. The invention further relates to the therapeutic efficacy of said
compounds, based on the combined antiproliferative, antiangiogenic and proapoptotic
capacities thereof, in the treatment of chronic psoriatic plaques.